Department of Pharmacology, Pennsylvania State College of Medicine, Hershey, Pennsylvania, USA.
Cancer Prev Res (Phila). 2013 Jul;6(7):719-30. doi: 10.1158/1940-6207.CAPR-12-0448. Epub 2013 May 16.
Raloxifene is a second-generation selective estrogen receptor modulator used for the prevention and treatment of osteoporosis and the prevention of breast cancer in postmenopausal women. Raloxifene is extensively metabolized by glucuronidation to form raloxifene-6-glucuronide (ral-6-Gluc) and raloxifene-4'-glucuronide (ral-4'-Gluc). The goal of the present study was to determine whether functional polymorphisms in active UGTs could play a role in altered raloxifene glucuronidation in vivo. Using homogenates from HEK293 UGT-overexpressing cell lines, raloxifene was shown to be glucuronidated primarily by the hepatic UGTs 1A1 and 1A9 and the extra-hepatic UGTs 1A8 and 1A10; no detectable raloxifene glucuronidation activity was found for UGT2B enzymes. Functional UGT1A1 transcriptional promoter genotypes were significantly (Ptrend = 0.005) associated with ral-6-Gluc formation in human liver microsomes, and, consistent with the decreased raloxifene glucuronidation activities observed in vitro with cell lines overexpressing UGT1A8 variants, the UGT1A8*2 variant was significantly (P = 0.023) correlated with total raloxifene glucuronide formation in human jejunum homogenates. While ral-4'-Gluc exhibited 1:100th the anti-estrogenic activity of raloxifene itself as measured by binding to the estrogen receptor, raloxifene glucuronides comprised about 99% of the circulating raloxifene dose in raloxifene-treated subjects, with ral-4'-Gluc comprising ~70% of raloxifene glucuronides. Plasma ral-6-Gluc (Ptrend = 0.0025), ral-4'-Gluc (Ptrend = 0.001), and total raloxifene glucuronides (Ptrend = 0.001) were increased in raloxifene-treated subjects who were predicted slow metabolizers [UGT1A8 (*1/*3)] versus intermediate metabolizers [UGT1A8 (*1/*1) or UGT1A8 (*1/*2)] versus fast metabolizers [UGT1A8 (*2/*2). These data suggest that raloxifene metabolism may be dependent on UGT1A8 genotype and that UGT1A8 genotype may play an important role in overall response to raloxifene.
雷洛昔芬是一种第二代选择性雌激素受体调节剂,用于预防和治疗绝经后妇女的骨质疏松症和乳腺癌。雷洛昔芬广泛通过葡萄糖醛酸化代谢为雷洛昔芬-6-葡萄糖醛酸(ral-6-Gluc)和雷洛昔芬-4'-葡萄糖醛酸(ral-4'-Gluc)。本研究的目的是确定功能性 UGT 中的活性多态性是否可以在体内改变雷洛昔芬的葡萄糖醛酸化。使用过表达 HEK293 UGT 的细胞系的匀浆,表明雷洛昔芬主要由肝 UGT1A1 和 1A9 和肝外 UGT1A8 和 1A10 进行葡萄糖醛酸化;未检测到 UGT2B 酶的雷洛昔芬葡萄糖醛酸化活性。功能性 UGT1A1 转录启动子基因型与人类肝微粒体中 ral-6-Gluc 的形成显著相关(Ptrend = 0.005),并且与细胞系中观察到的 UGT1A8 变体的雷洛昔芬葡萄糖醛酸化活性降低一致,UGT1A8*2 变体与人类空肠匀浆中总雷洛昔芬葡萄糖醛酸化物的形成显著相关(P = 0.023)。虽然 ral-4'-Gluc 的抗雌激素活性仅为雷洛昔芬本身的 1/100,如通过与雌激素受体结合所测量,但雷洛昔芬葡萄糖醛酸化物约占雷洛昔芬治疗受试者中循环雷洛昔芬剂量的 99%,其中 ral-4'-Gluc 约占雷洛昔芬葡萄糖醛酸化物的 70%。雷洛昔芬治疗受试者的血浆 ral-6-Gluc(Ptrend = 0.0025)、ral-4'-Gluc(Ptrend = 0.001)和总雷洛昔芬葡萄糖醛酸化物(Ptrend = 0.001)在预测为代谢缓慢的受试者 [UGT1A8(*1/*3)] 中增加,与中间代谢者 [UGT1A8(*1/*1)或 UGT1A8(*1/*2)] 相比,与快速代谢者 [UGT1A8(*2/*2)]。这些数据表明,雷洛昔芬代谢可能依赖于 UGT1A8 基因型,并且 UGT1A8 基因型可能在雷洛昔芬的整体反应中发挥重要作用。